Miscellaneous Neoplasm - Other

NCT01503515

Clinical Trial Information

Trial Number: NCT01503515 (ClinicalTrials.gov)

Disease Type:

Immune Disorder (excluding AIDS and malignancy) - Miscellaneous
Miscellaneous Neoplasm - Other

Trial Title:

A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)

Study ID:

ACCL1131

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT01503515-D2	NCT01503515-D2: There are 2 datasets associated with PMID 33136159. This dataset, NCT01503515-D2, provides the information for the demographic baseline characteristics (Table 1), transplant baseline characteristics (Table 2), post-randomization factors (Table 3), cumulative incidence and other outcomes (Table 4 & Figure 2) and organisms causing the invasive fungal disease (Table 5). There is one row per patient. NCT01503515-D1 contains the data reported in the CONSORT diagram in the manuscript (Figure 1).
NCT01503515-D1	NCT01503515-D1: There are 2 datasets associated with PMID 33136159. This dataset, NCT01503515-D1, provides the information for the CONSORT diagram in the manuscript (Figure 1). Data provided for all enrolled patients (N=292). There is one row per patient. NCT01503515-D2 contains data on baseline characteristics, post-randomization factors, cumulative incidence, and organism details.

Title

Description

NCT01503515-D2

NCT01503515-D2: There are 2 datasets associated with PMID 33136159. This dataset, NCT01503515-D2, provides the information for the demographic baseline characteristics (Table 1), transplant baseline characteristics (Table 2), post-randomization factors (Table 3), cumulative incidence and other outcomes (Table 4 & Figure 2) and organisms causing the invasive fungal disease (Table 5). There is one row per patient. NCT01503515-D1 contains the data reported in the CONSORT diagram in the manuscript (Figure 1).

NCT01503515-D1

NCT01503515-D1: There are 2 datasets associated with PMID 33136159. This dataset, NCT01503515-D1, provides the information for the CONSORT diagram in the manuscript (Figure 1). Data provided for all enrolled patients (N=292). There is one row per patient. NCT01503515-D2 contains data on baseline characteristics, post-randomization factors, cumulative incidence, and organism details.

NCT01817075

Clinical Trial Information

Trial Number: NCT01817075 (ClinicalTrials.gov)

Disease Type:

Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma) - Miscellaneous
Miscellaneous Neoplasm - Other
Miscellaneous Neoplasm - Solid Tumor

Trial Title:

Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)

Study ID:

ACCL1034

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT01817075-D5	NCT01817075-D5: There are 5 datasets associated with PMID 33079403. This dataset, NCT01817075-D5, provides organisms identified from positive blood cultures (Figure 3). The number of rows per patient is dependent on number of organisms submitted.
NCT01817075-D4	NCT01817075-D4: There are 5 datasets associated with PMID 33079403. This dataset, NCT01817075-D4, provides cutaneous adverse event information during the study period (Table 4 & Figure 4). The number of rows per patient is dependent on number of cutaneous adverse events submitted.
NCT01817075-D3	NCT01817075-D3: There are 5 datasets associated with PMID 33079403. This dataset, NCT01817075-D3, provides more detailed information on the cutaneous staphylococci isolates (as mentioned in the text of the manuscript). Data provided for all eligible and evaluable patients (N=174 patients) who submitted baseline and at least 1 follow-up swab (N=1046 swabs). The number of rows per patient is dependent on number of samples submitted.
NCT01817075-D2	NCT01817075-D2: There are 5 datasets associated with PMID 33079403. This dataset, NCT01817075-D2, provides the information for baseline characteristics (Table 1), all primary, secondary and post-hoc analyses (Table 2), general isolate data (Table 3), time to event analysis (Figure 2), Supporting Information (eTables 1-2) and other results reported in the manuscript. Data provided for all eligible patients (N=175) but the analysis is limited to all evaluable patients (N=174, CONSORT06≠Excluded in analysis). There is one row per patient.
NCT01817075-D1	NCT01817075-D1: There are 5 datasets associated with PMID 33079403. This dataset, NCT01817075-D1, provides the information for the consort diagram in the manuscript (Figure 1). Data provided for all enrolled patients (N=177). There is one row per patient.

NCT02054715

Clinical Trial Information

Trial Number: NCT02054715 (ClinicalTrials.gov)

Disease Type:

Miscellaneous Neoplasm - Other

Trial Title:

Evaluation of Psychoeducation for Cancer Patients Eligible for Clinical Trials

Study ID:

URCC-12107

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT02054715-D1	This dataset from trial NCT02054715 contains patients' preparedness for decision making about clinical trials (via the Preparation for Decision Making Scale), comparing Multimedia Psychoeducation (MP) and Print Education (PE) interventions. The results are documented in PubMed (PMID) 30291797. Bennett C, Graham ID, Kristjansson E, Kearing SA, Clay KF, O'Connor AM. Validation of a preparation for decision making scale. Patient education and counseling. 2010;78:130-133.

Title

Description

NCT02054715-D1

This dataset from trial NCT02054715 contains patients' preparedness for decision making about clinical trials (via the Preparation for Decision Making Scale**), comparing Multimedia Psychoeducation (MP) and Print Education (PE) interventions. The results are documented in PubMed (PMID) 30291797.
** Bennett C, Graham ID, Kristjansson E, Kearing SA, Clay KF, O'Connor AM. Validation of a preparation for decision making scale. Patient education and counseling. 2010;78:130-133.

NCT00397930

Clinical Trial Information

Trial Number: NCT00397930 (ClinicalTrials.gov)

Disease Type:

Miscellaneous Neoplasm - Other

Trial Title:

Yoga for Persistent Sleep Disturbance in Cancer Survivors

Study ID:

URCC-04-01

Images are available?:

Is this a NCI-MATCH Trial?:

NCT00081250

Clinical Trial Information

Trial Number: NCT00081250 (ClinicalTrials.gov)

Disease Type:

Miscellaneous Neoplasm - Other

Trial Title:

Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Creatine for Cancer-Associated Weight Loss

Study ID:

N02C4

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00081250-D2	Dataset NCT00081250-D2-Dataset.csv (demo) is one of 2 datasets associated with PubMed ID 28475678. This dataset contains information that will allow you to reproduce the baseline characteristics table, primary analysis, and adverse event analysis.
NCT00081250-D1	Dataset NCT00081250-D1-Dataset.csv (qol) is one of 2 datasets associated with PubMed ID 28475678. This dataset contains information that will allow you to reproduce the primary analysis as well as other quality of life analyses.

NCT00459134

Clinical Trial Information

Trial Number: NCT00459134 (ClinicalTrials.gov)

Disease Type:

Miscellaneous Neoplasm - Other

Trial Title:

A Randomized Study to Determine Whether ArginMax Improves the Sexual Function and Quality of Life in Female Cancer Survivors

Study ID:

WFU-05-04-01

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT00459134-D1	This dataset contains all the data used in the publication cited above (PMID=26287032). Baseline demographic and clinical variables are provided for time = 0 (baseline visit). The primary outcome measures for the study are assessed at each time (0=baseline, 4=4 weeks, 8=8 weeks, and 12=12 weeks). Summary measures that are calculated across the participant’s time on study (e.g., worst toxicities and compliance) are recorded on the time = 99 rows. Note that these are measures determined over the entire study period, not a specific time. Notes: Missing data are denoted by a blank or a ‘.’ for each variable.

Title

Description

NCT00459134-D1

This dataset contains all the data used in the publication cited above (PMID=26287032).
Baseline demographic and clinical variables are provided for time = 0 (baseline visit).
The primary outcome measures for the study are assessed at each time (0=baseline, 4=4 weeks, 8=8 weeks, and 12=12 weeks).
Summary measures that are calculated across the participant’s time on study (e.g., worst toxicities and compliance) are recorded on the time = 99 rows. Note that these are measures determined over the entire study period, not a specific time.
Notes: Missing data are denoted by a blank or a ‘.’ for each variable.

NCT02116530

Clinical Trial Information

Trial Number: NCT02116530 (ClinicalTrials.gov)

Disease Type:

Miscellaneous Neoplasm - Carcinoma, Miscellaneous
Miscellaneous Neoplasm - Other

Trial Title:

Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Randomized, Double-Blind, Placebo-Controlled Trial

Study ID:

A221301

Images are available?:

Is this a NCI-MATCH Trial?:

Datasets Linked to Trial

Title	Description
NCT02116530-D2	Dataset NCT02116530-D2-Dataset.csv (aedat) is one of 2 datasets associated with PubMed ID 27410922. This dataset contains information that will allow you to reproduce the adverse events analyses. Due to cleaning efforts subsequent to the publication, the data contains some minor discrepancies from those reported in the manuscript.
NCT02116530-D1	Dataset NCT02116530-D1-Dataset.csv (master) is one of 2 datasets associated with PubMed ID 27410922. This dataset contains information that will allow you to reproduce the baseline characteristics table and primary analysis.

Subscribe to Miscellaneous Neoplasm - Other

Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security

U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov

NIH…Turning Discovery Into Health^®